View Older Stories View More Recent Stories

Feb 16, 2022 06:00AM William Blair Reiterates Outperform Rating on Alteryx (AYX), Sees Stock as Materially Undervalued and as a Buying Opportunity

Feb 16, 2022 03:13AM Truist Securities Reiterates CRISPR (CRSP) at Buy, Q4 Results Underscore Continued Execution on Multiple Fronts, "We Are Strong Buyers"

Feb 16, 2022 03:10AM Stifel Reiterates Mirati (MRTX) at Buy, adagrasib Approval is Likely, But Shares May be Weak as Drug Was Not Accepted For Priority Review

Feb 16, 2022 03:06AM Mirati (MRTX) Reiterated at Outperform by Cowen, Dec PDUFA is a Surprise but Earlier Approval Possible, Doesn't Change Valuation

Feb 15, 2022 11:42AM H.C. Wainwright Reiterates Buy Rating, $5 PT on Palatin Technologies (PTN) Following Q2 Report

Feb 15, 2022 10:59AM Dawson James Reiterates Buy Rating, $10 PT on Citius (CTXR), Phase 2b of Galo-Lido is a Logical and Pragmatic Move

Feb 15, 2022 08:40AM Truist Securities Reiterates Buy Rating on Intellia (NTLA) Following ONK Collaboration, The Deal Leverages NTLA's Genome Editing Expertise

Feb 15, 2022 08:10AM Stifel Reiterates Cerevel (CERE) at Buy, M4 Has Blockbuster Potential, the Rest of Pipeline Offers Attractive Optionality

Feb 15, 2022 07:48AM Cantor Fitzgerald Reiterates Zoetis (ZTS) at Overweight, Earnings Potential of Underlying Business is Still Underappreciated

Feb 15, 2022 06:23AM Needham & Company Reiterates Buy Rating on Seagen (SGEN), Latest EV-103 Data is Very Encouraging

Feb 15, 2022 06:21AM Collegium Pharmaceutical (COLL) PT Hiked to $34 at Needham & Company on Anticipated BioDelivery (BDSI) Synergies

Feb 15, 2022 06:18AM Acasti Pharma (ACST) PT Lowered to $5 at Oppenheimer, Analyst Still Recommends "Building a Position" Given Multiple Upcoming Clinical Milestones

Feb 15, 2022 06:14AM Clene, Inc. (CLNN) PT Lowered to $19 at Oppenheimer, but Reiterated Optimism for CNM-Au8's Top-line Phase 2/3 results in ALS

Feb 15, 2022 06:12AM Kodiak (KOD) Reiterated at Buy by Truist Securities, Analyst Believes wAMD Trial Will be Successful, Models Peak Sales of $2.7B

Feb 15, 2022 06:07AM BioXcel Therapeutics (BTAI) Reiterated at Buy by Truist, Continue to see 701 as Monetizable Opportunity

Feb 15, 2022 06:00AM Cantor Fitzgerald Reiterates Overweight Rating on Aytu Biosciences (AYTU), Company's Transformation Remains Underappreciated

Feb 15, 2022 05:58AM Truist Securities Reiterates Buy Rating on Roivant Sciences (ROIV), "Continue to See Pipeline Execution"

Feb 15, 2022 05:55AM BMO Capital Reiterates Market Perform Rating on Amgen (AMGN) on Recent Lumakras Data

Feb 14, 2022 05:54AM Oppenheimer Reiterates Outperform Rating on Opiant Pharma (OPNT), "Expect Upcoming Data to Illustrate Advantage for OPNT003"

Feb 14, 2022 05:51AM Needham & Company Reiterates Neurocrine (NBIX) at Hold, "Love Execution on Ingrezza" but Cautious on Future Pipeline Readouts

Feb 14, 2022 05:48AM Bristol-Myers Squibb Co. (BMY) PT Raised to $76 at Truist Securities, Revlimid Erosion Remains Key Investor Concern

Feb 11, 2022 04:41PM Neurocrine (NBIX) Maintained at Underperform by BMO, PT Hiked to $74, Analyst Sees Challenging Q1

Feb 11, 2022 04:22PM Stifel Reiterates Buy Rating on Orchard Therapeutics (ORTX), Positive Updates Continue to Reinforce Optimism

Feb 11, 2022 04:16PM Raymond James Reiterates Passage (PASG) at Outperform, Encouraged to See GM1 Readout, See Significant Upside in the Stock

Feb 11, 2022 03:50PM Stifel Reiterates Buy Rating on Freeline (FRLN), Optimistic on FLT190 Despite Increasing Competition

Feb 11, 2022 11:44AM Raymond James Reiterates Outperform Rating on Neurocrine Bio. (NBIX), Company is Well Positioned to Execute as COVID Dissipates

Feb 11, 2022 11:33AM UPDATE: ProQR Therapeutics (PRQR) Downgraded to Hold at Stifel, PT Slashed to $3, sepofarsen Revenues Removed From Model

Feb 11, 2022 10:09AM Neurocrine Bio. (NBIX) PT Lowered to $136 at Stifel, Ingrezza's Growth and Sales, and Pipeline Prospects Remain Key Focus for Investors,

Feb 11, 2022 10:05AM UPDATE: Y-mAbs Therapeutics (YMAB) Reiterated at Outperform by Cowen, Progress is Encouraging, Shares are Undervalued

Feb 11, 2022 09:46AM BMO Capital Reiterates Regeneron Pharma (REGN) at Outperform, "Eylea Phase 2 Data Supportive of Likely Positive Phase 3"

Feb 11, 2022 09:05AM Stifel Reiterates Kinnate Biopharma (KNTE) at Buy, Optimistic That KIN-287 Can Improve Efficacy

Feb 11, 2022 08:24AM William Blair Reiterates Outperform Rating on VistaGen Therapeutics (VTGN)

Feb 11, 2022 08:19AM Needham & Company Reiterates Hold on Neurocrine (NBIX), Calls Earnings Uneventful, Does Not Expect Big Move in Stock

Feb 11, 2022 08:09AM BMO Capital Reiterates Neurocrine (NBIX) at Outperform, But Notes Post-Pandemic Headwinds to Achieving Guidance

Feb 11, 2022 07:48AM Stifel Sees 60% Downside to ProQR (PRQR) on Ph.2/3 ILLUMINATE Data, Model Under Review

Feb 11, 2022 05:25AM Stifel Reiterates Buy on Ultragenyx (RARE), Results Suggest Stable and Growing Business, Pipeline Has Multiple Value Creation Opportunities

Feb 11, 2022 05:22AM Stifel Reiterates Hold Rating on Homology Medicines (FIXX), Upcoming HMI-102 Data Continues to Represent Important Binary Catalyst

Feb 11, 2022 05:16AM Ultragenyx (RARE) Reiterated at Buy by Truist Securities, Latest Data Gives Confidence that GTX-102 is Working

Feb 11, 2022 05:13AM Alnylam (ALNY) PT Raised to $205 at Oppenheimer, Shares Look Attractive Into 2022 Business and Catalysts

Feb 10, 2022 01:50PM Needham & Company Reiterates Biogen (BIIB) at Buy Ahead of CMS Decision, but Notes It's Hard to Predict

Feb 10, 2022 01:40PM Oppenheimer Reiterates Teva Pharma (TEVA) at Perform, Notes Progress and Improvements Despite the Miss on Numbers

Feb 10, 2022 10:42AM Anavex Life Sciences (AVXL) PT Raised to $39 at Dawson James

Feb 10, 2022 10:28AM Amgen (AMGN) PT Raised to $263 at Truist Securities, Company is "De-risked of Binary Events"

Feb 10, 2022 08:25AM Cantor Fitzgerald Reiterates SCYNEXIS (SCYX) at Overweight, Company Continues to be Undervalued

Feb 10, 2022 07:20AM Truist Securities Reiterates Aptinyx (APTX) at Buy, Downside is Limited, While Upside Could be Significant

Feb 10, 2022 07:14AM Truist Securities Reiterates Viking Therapeutic (VKTX) at Buy, Continues to View VK2809 as Superior to resmetirom, Stock Remains Top 5 Pick for 2022

Feb 10, 2022 04:31AM Stifel Reiterates Fulcrum (FULC) at Buy, Potential for a "String of Positive Data" with "Significant Revenue Opportunities"

Feb 9, 2022 05:57PM Veru (VERU) PT Lowered to $25 at Oppenheimer, but Reiterated as Top Pick, "Stock Offers Desirable Profile Among Small Caps"

Feb 9, 2022 05:16PM Avrobio's (AVRO) ARV-RD-04 Phase 1/2 Provide Proof-of-Concept, Represent a Free Call Option on Stock - Mizuho Securities

Feb 9, 2022 03:39AM Pfizer (PFE) PT Hiked to $62 at Truist Securities, "See Guidance as Conservative"

View More Recent Stories View Older Stories